BRAF and neoplasm: Similarly, targeted inhibition of B-Raf proto-oncogene, serine/threonine kinase) (BRAF) signaling can induce initial tumor regression but often leads to metabolic rewiring and reactivation of survival pathways, ultimately promoting recurrence.